TRACON Pharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Conference
TRACON Pharmaceuticals (NASDAQ: TCON) announced that Charles Theuer, M.D., Ph.D., will present a corporate overview at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. This presentation will be available on-demand starting March 9, 2021, on TRACON's website. The company focuses on developing targeted cancer therapies and has a pipeline that includes Envafolimab for sarcoma, TRC253 for prostate cancer, TRC102 for lung cancer, and TJ004309 for advanced solid tumors. TRACON seeks corporate partnerships to enhance U.S. clinical development and commercialization.
- None.
- None.
SAN DIEGO, March 02, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright Global Life Sciences Conference, being held virtually March 9-10, 2021.
The presentation will be available on-demand beginning on Tuesday, March 9, 2021, in the Investors section on the Company’s website at www.traconpharma.com.
About TRACON
TRACON develops targeted therapies for cancer utilizing a capital efficient, CRO independent, product development platform. The Company’s clinical-stage pipeline includes: Envafolimab, a PD-L1 single-domain antibody given by rapid subcutaneous injection that is being studied in the pivotal ENVASARC trial for sarcoma; TRC253, a Phase 3 ready small molecule drug candidate for the treatment of prostate cancer; TRC102, a Phase 2 small molecule drug candidate for the treatment of lung cancer; and TJ004309, a CD73 antibody in Phase 1 development for the treatment of advanced solid tumors. TRACON is actively seeking additional corporate partnerships whereby it leads U.S. regulatory and clinical development and shares in the cost and risk of clinical development and leads U.S. commercialization. In these partnerships TRACON believes it can serve as a solution for companies without clinical and commercial capabilities in the U.S. To learn more about TRACON and its product pipeline, visit TRACON's website at www.traconpharma.com.
| Company Contact: | Investor Contact: |
| Mark Wiggins | Andrew McDonald |
| Chief Business Officer | LifeSci Advisors LLC |
| (858) 251-3492 | 646-597-6987 |
| mwiggins@traconpharma.com | Andrew@lifesciadvisors.com |
FAQ
When will TRACON Pharmaceuticals present at the H.C. Wainwright Global Life Sciences Conference?
How can I access the TRACON Pharmaceuticals presentation?
What are some key products in TRACON's pipeline?
What type of therapies does TRACON Pharmaceuticals focus on?
What is the goal of TRACON's corporate partnerships?
